Overview

Trial of CF101 to Treat Patients With Psoriasis

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Can-Fite BioPharma